CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14)

Critical Care Medicine

Volumn 32, Issue 5, 2004, Pages 1100-1108

  Reinhart, Konrad ^a   Glück, Thomas ^b   Ligtenberg, Jack ^c   Tschaikowsky, Klaus ^d   Bruining, Albert ^e   Bakker, Jan ^f   Opal, Steven ^g   Moldawer, Lyle L ^h   Axtelle, Tim ⁱ   Turner, Terence ⁱ   Souza, Sonia ⁱ   Pribble, John ⁱ  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f GELRE HOSPITALS   (Netherlands)

^g BROWN UNIVERSITY   (United States)

^h UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

ⁱ ICDS Corporation   (United States)

Author keywords

CD14; Monoclonal antibody; Multiple organ dysfunction; Pattern recognition; Sepsis; Severe sepsis

Indexed keywords

ACUTE PHASE PROTEIN; AUTACOID; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CHEMOKINE; CHIMERIC ANTIBODY; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE BINDING PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD14; PLACEBO; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ADULT; ANAPHYLAXIS; ANTIBODY PRODUCTION; ANTIBODY TITER; AREA UNDER THE CURVE; BONE MARROW CELL; CANDIDIASIS; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DISTRIBUTION VOLUME; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ENDOTOXEMIA; ENZYME IMMUNOASSAY; FEMALE; GERMANY; HUMAN; HYPOTENSION; INFECTION RISK; INTENSIVE CARE UNIT; MALE; MONOCYTE; MULTICENTER STUDY; MULTIPLE DRUG DOSE; NETHERLANDS; OUTCOMES RESEARCH; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RASH; RECEPTOR BINDING; RECEPTOR OCCUPANCY; REVIEW; SEPSIS; SINGLE DRUG DOSE; SUPERINFECTION;

ACUTE-PHASE PROTEINS; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD14; AREA UNDER CURVE; BACTERIAL INFECTIONS; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; E-SELECTIN; FEMALE; GERMANY; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MONOCYTES; NETHERLANDS; RECOMBINANT FUSION PROTEINS; SAFETY; SEPSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2442565752     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000124870.42312.C4     Document Type: Review

References (48)

1. Angus DC, Linde-Zwirble WT, Lidicker J, et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310
2. Alberti C, Brun-Buisson C, Burchardi H, et al: Epidemiology of sepsis and infection in ICU patients from an international mulitcentre cohort study. Crit Care Med 2001; 28: 108-121
3. Martin GS, Mannino DM, Eaton S, et al: The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554
4. Tracey KI, Beutler B, Lowry SF, et al: Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-474
5. Michie HR, Spriggs DR, Manogue KR, et al: Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 1988; 104:280-286
6. Cannon JG, Tompkins RG, Gelfand JA, et al: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990; 161:79-84
7. Smith JW, Urba WJ, Curti BD, et al: The toxic and hematological effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancy. J Clin Oncol 1992; 10:1141-1152
8. Wright SD: CD14 and innate recognition of bacteria. J Immunol 1995; 155:6-8
9. Antal-Szalmas P: Evaluation of CD14 in host defense. Eur J Clin Invest 2000; 30:167-179
10. Beutler B: Tlr4: Central component of the sole mammalian LPS sensor. Curr Opin Immunol 2000; 12:20-26
11. Compton T, Kurt-Jones EA, Boehme KW, et al: Human cytomegalovirus activates inflammatory cytokine responses via CD14 and toll-like receptor 2. J Virol 2003; 77:4588-4596
12. Pugin J, Heumann ID, Tomasz A, et al: CD14 is a pattern recognition receptor. Immunity 1994; 1:509-516
13. Schmitz G, Orso E: CD14 signalling in lipid rafts: New ligands and co-receptors. Curr Opin Lipidol 2002; 13:513-521
14. Triantafilou M, Brandenburg K, Gutsmann T, et al: Innate recognition of bacteria: Engagement of multiple receptors. Crit Rev Immunol 2002; 22:251-268
15. Beutler B, Hoebe K, Du X, et al: How we detect microbes and respond to them: the Toll-like receptors and their transducers. J Leukoc Biol; 74:479-485
16. Parillo JE: Pathogenic mechanisms of septic shock. N Engl J Med 1993; 328:1471-1478
17. 2 integrin in vivo. J Leukoc Biol 1996; 59:145-151
18. Stelter F, Bernheiden M, Menzel R, et al: The molecular basis for therapeutic concepts utilizing CD14. Prog Clin Biol Res 1998; 397: 301-313
19. Hotchkiss RS, Karl IE: The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348:138-150
20. Marshall JC: Inflammation, coagulopathy, and the pathogenesis of multiple organ dysfunction syndrome. Crit Care Med 2001; 29: S99-S106
21. Axtelle T, Pribble J: IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res 2001; 7:310-314
22. Verbon A, Dekkers PEP, ten Hove T, et al: IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol 2001; 166: 3599-3605
23. Knaus W, Draper E, Wagner D, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829
24. Marshall J, Cook D, Christou N, et al: Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1652
25. Ferrero E, Jiao D, Tsuberi BZ, et al: Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc Nat Acad Sci U S A 1993; 90:2380-2384
26. Haziot A, Ferrero E, Kontgen F, et al: Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996; 4:407-414
27. Schimke J, Mathison J, Morgiewicz J, et al: Anti-CD14 mAb treatment provides therapeutic benefit after in vivo exposure to endotoxin. Proc Nat Acad Sci U S A 1998; 95: 13875-13880
28. Leturcq DJ, Moriarity AM, Talbott G, et al: Antibodies against CD14 protect primates from endotoxin-induced shock. J Clin Invest 1996; 98:1533-1538
29. Tcheng JE, Kereiakes DJ, Braden GA, et al: Readministration of abciximab: Interim report of the ReoPro readministration registry. Am Heart J 1999; 138:S33-S38
30. Diamanti A, Castro M, Papadatou B, et al: Severe anaphylactic reaction to infliximab in pediatric patients with Crohn's disease. J Pediatr 2002; 140:636-637
31. Furusako S, Takahashi T, Mori S, et al: Protection of mice from LPS-induced shock by CD14 antisense oligonucleotide. Acta Med Okayama 2001; 55:105-115
32. Schultz MJ, van der Poll T: Animal and human models for sepsis. Ann Med 2002; 34: 573-581
33. Monneret G, Debard A-L, Venet F, et al: Marked elevation of human circulating CD4+CD25+ regulatory T cells in sepsis-induced immunoparalysis. Crit Care Med 2003; 31:2068-2071
34. Grunwald U, Fan X, Jack RS, et al: Monocytes can phagocytose Gram-negative bacteria by a CD14-dependent mechanism. J Immunol 1996; 157:4119-4125
35. Frevert CW, Matute-Bello G, Skerrett SJ, et al: Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J Immunol 2000; 164:5439-5455
36. Netea MG, Van der Graaf CAA, Vonk AG, et al: The role of toll-like receptor (TLR) 2 and TLR4 in the host defense against disseminated Candidiasis. J Infect Dis 2002; 185: 1483-1489
37. Marr KA, Balajee SA, Hwan TR, et al: Differential role of MyD88 in macrophage-mediated responses to opportunistic fungal pathogens. Infect Immun 2003; 71:5280-5286
38. Opal SM, Palardy JE, Parejo N, et al: The effect of anti-CD14 monoclonal antibody on clearance of Escherichia coli bacteremia and endotoxemia. Crit Care Med 2003; 31:929-932
39. Burgmann H, Winkler S, Locker GJ, et al: Increased serum concentration of soluble CD14 is a prognostic marker in Gram-positive sepsis. Clin Immunol Immunopathol 1996; 80:307-310
40. Landmann R, Zimmerli W, Sansano S, et al: Increased circulating soluble CD14 is associated with high mortality in Gram-negative septic shock. J Infect Dis 1995; 171:639-644
41. Haziot A, Rong GW, Lin X-Y, et al: Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995; 154:6529-6532
42. Arditi M, Zhou J, Dorio R, et al: Endotoxin-mediated endothelial cell injury and activation: Role of soluble CD14. Infect Immun 1993; 61:3149-3156
43. Loppnow H, Stelter F, Schönbeck U, et al: Endotoxin activates human vascular smooth muscle cells despite lack of expression of CD14 mRNA or endogenous membrane CD14. Infect Immun 1995; 63:1020-1026
44. Pugin J, Schurer-Maly CC, Leturcq D, et al: Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD 14. Proc Nat Acad Sci U S A 1993; 90:2744-2748
45. Baldini M, Lohman JC, Halonen M, et al: A polymorphism in the 5 flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20:976-983
46. Hubacek JA, Pit'ha J, Skodova Z, et al: C(-260)→T polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999; 99:3218-3220
47. Agnese DM, Calvano JE, Hahm SJ, et al: Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections. J Infect Dis 2002; 186: 1522-1525
48. Gibot S, Cariou A, Drouet L, et al: Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002; 30:969-973